Long-term use of omalizumab in patients with allergic bronchopulmonary aspergillosis: a tertiary-level care center experience
- 8 July 2024
- journal article
- research article
- Published by Taylor & Francis in Journal of Asthma
- Vol. 61 (12) , 1663-1671
Abstract
IntroductionAllergic bronchopulmonary aspergillosis (ABPA) is a lung disease caused by a hypersensitivity reaction to antigens of Aspergillus fumigatus.ObjectiveThe aim of this study was to evaluate the long-term clinical outcomes of omalizumab use in patients with ABPA.MethodsIn this retrospective study, 12 patients diagnosed with ABPA and receiving omalizumab for at least 2 years, and 32 patients diagnosed with severe allergic asthma and receiving omalizumab for at least 2 years (control group) were evaluated.ResultsEvaluation was made of a total of 44 participants, comprising 11 (25%) males and 33 (75%) females, who received omalizumab for at least 2 years with the diagnosis of the control group (n = 32) and ABPA (n = 12). The increase in asthma control test (ACT) score after omalizumab was significant at 12 months and at 24 months in patients with ABPA. After omalizumab, the use of oral corticosteroid (OCS), the annual number of asthma attacks and hospitalizations were significantly decreased at 12 months and at 24 months in patients with ABPA. The increase in forced expiratory volume in 1 s (FEV1) (%) and ACT score after omalizumab were significant at 12 months and at 24 months in the control group. After omalizumab, the use of OCS, annual number of asthma attacks and hospitalizations were significantly decreased at 12 months and at 24 months in the control group.ConclusionLong-term omalizumab use in patients with ABPA seems to be an effective treatment for improving pulmonary function and reducing asthma exacerbations and hospitalizations.Keywords
This publication has 30 references indexed in Scilit:
- Efficacy of omalizumab in adult patients with allergic bronchopulmonary aspergillosis: a multicentre study in ChinaClinical and Experimental Medicine, 2024
- Real-world efficacy of anti-IL-5 treatment in patients with allergic bronchopulmonary aspergillosisScientific Reports, 2023
- Omalizumab in Allergic Bronchopulmonary Aspergillosis: A Systematic Review and Meta-AnalysisJournal of Allergy and Clinical Immunology, 2022
- Long-term effectiveness and safety of omalizumab in pediatric and adult patients with moderate-to-severe inadequately controlled allergic asthmaWorld Allergy Organization Journal, 2022
- Successful management of recurrent allergic bronchopulmonary aspergillosis after changing from mepolizumab to dupilumab: A case reportRespiratory Medicine Case Reports, 2022
- Omalizumab for asthma and allergic bronchopulmonary aspergillosis in adults with cystic fibrosisJournal of Cystic Fibrosis, 2020
- Beneficial effects of Omalizumab therapy in allergic bronchopulmonary aspergillosis: A synthesis review of published literatureRespiratory Medicine, 2017
- Anti-IgE therapy for allergic bronchopulmonary aspergillosisJournal of Microbiology, Immunology and Infection, 2016
- Clinical Efficacy and Immunologic Effects of Omalizumab in Allergic Bronchopulmonary AspergillosisThe Journal of Allergy and Clinical Immunology: In Practice, 2015
- Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteriaClinical & Experimental Allergy, 2013